Jundishapur Journal of Microbiology

Published by: Kowsar

Microdilution in vitro Antifungal Susceptibility Patterns of Candida Species, From Mild Cutaneous to Bloodstream Infections

Elham Rezazadeh 1 , Azar Sabokbar 1 , Maryam Moazeni 2 , Mohammad Sadegh Rezai 3 and Hamid Badali 4 , *
Authors Information
1 Department of Microbiology, Karaj Branch, Islamic Azad University, Karaj, IR Iran
2 Department of Medical Mycology and Parasitology, Invasive Fungi Research Center, School of Medicine, Mazandaran University of Medical Sciences, Sari, IR Iran
3 Infection Diseases Research Center with Focus on Nosocomial Infection, Mazandaran University of Medical Sciences, Sari, IR Iran
4 Department of Medical Mycology and Parasitology, Infection Diseases Research Center with Focus on Nosocomial Infection, Mazandaran University of Medical Sciences, Sari, IR Iran
Article information
  • Jundishapur Journal of Microbiology: July 01, 2016, 9 (7); e34151
  • Published Online: July 5, 2016
  • Article Type: Research Article
  • Received: March 9, 2016
  • Revised: June 11, 2016
  • Accepted: June 25, 2016
  • DOI: 10.5812/jjm.34151

To Cite: Rezazadeh E, Sabokbar A, Moazeni M, Rezai M S, Badali H. Microdilution in vitro Antifungal Susceptibility Patterns of Candida Species, From Mild Cutaneous to Bloodstream Infections, Jundishapur J Microbiol. 2016 ; 9(7):e34151. doi: 10.5812/jjm.34151.

Copyright © 2016, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis. 2009; 48(12): 1695-703[DOI][PubMed]
  • 2. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007; 20(1): 133-63[DOI][PubMed]
  • 3. Bougnoux ME, Kac G, Aegerter P, d'Enfert C, Fagon JY, CandiRea Study G. Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome. Intensive Care Med. 2008; 34(2): 292-9[DOI][PubMed]
  • 4. Pfaller MA, Jones RN, Doern GV, Sader HS, Messer SA, Houston A, et al. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother. 2000; 44(3): 747-51[PubMed]
  • 5. Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001. J Clin Microbiol. 2003; 41(4): 1440-6[PubMed]
  • 6. Ribeiro MA, Dietze R, Paula CR, Da Matta DA, Colombo AL. Susceptibility profile of vaginal yeast isolates from Brazil. Mycopathologia. 2001; 151(1): 5-10[PubMed]
  • 7. Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol. 2005; 43(5): 2155-62[DOI][PubMed]
  • 8. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother. 1995; 39(1): 1-8[PubMed]
  • 9. Yazdanparast SA, Khodavaisy S, Fakhim H, Shokohi T, Haghani I, Nabili M, et al. Molecular Characterization of Highly Susceptible Candida africana from Vulvovaginal Candidiasis. Mycopathologia. 2015; 180(5-6): 317-23[DOI][PubMed]
  • 10. de Hoog GS, Guarro J, Gené J, Figueras MJ. Atlas of clinical fungi. 2000;
  • 11. Fesharaki SH, Haghani I, Mousavi B, Kargar ML, Boroumand M, Anvari MS, et al. Endocarditis due to a co-infection of Candida albicans and Candida tropicalis in a drug abuser. J Med Microbiol. 2013; 62: 1763-7[DOI][PubMed]
  • 12. Reference method for broth dilution antifungal susceptibility testing of yeasts: Approved standard-third edition. 2008;
  • 13. Reference method for broth dilution antifungal susceptibility testing of yeasts: Fourth informational supplement . 20012;
  • 14. Afsarian MH, Badali H, Boekhout T, Shokohi T, Katiraee F. Multilocus sequence typing of Candida albicans isolates from a burn intensive care unit in Iran. J Med Microbiol. 2015; 64: 248-53[DOI][PubMed]
  • 15. Batavia AS, Secours R, Espinosa P, Jean Juste MA, Severe P, Pape JW, et al. Diagnosis of hiv-associated oral lesions in relation to early versus delayed antiretroviral therapy: Results from the cipra ht001 trial. PLoS One. 2016; 11(3)[DOI][PubMed]
  • 16. Badiee P, Alborzi A, Davarpanah MA, Shakiba E. Distributions and antifungal susceptibility of Candida species from mucosal sites in HIV positive patients. Arch Iran Med. 2010; 13(4): 282-7[PubMed]
  • 17. Capoor MR, Nair D, Deb M, Verma PK, Srivastava L, Aggarwal P. Emergence of non-albicans Candida species and antifungal resistance in a tertiary care hospital. Jpn J Infect Dis. 2005; 58(6): 344-8[PubMed]
  • 18. Sobel JD, Ohmit SE, Schuman P, Klein RS, Mayer K, Duerr A, et al. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis. 2001; 183(2): 286-93[DOI][PubMed]
  • 19. Panizo M, Reviakina V, Dolande M, Selgrad S. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains. Med Mycol. 2009; 47(2): 137-43[DOI]
  • 20. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Doern GV, Brandt ME, et al. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn Microbiol Infect Dis. 1999; 33(4): 217-22[DOI][PubMed]
  • 21. Godoy P, Tiraboschi IN, Severo LC, Bustamante B, Calvo B, Almeida LP, et al. Species distribution and antifungal susceptibility profile of Candida spp. bloodstream isolates from Latin American hospitals. Mem Inst Oswaldo Cruz. 2003; 98(3): 401-5[PubMed]
  • 22. Gomez J, Garcia-Vazquez E, Espinosa C, Ruiz J, Canteras M, Hernandez-Torres A, et al. Nosocomial candidemia at a general hospital: the change of epidemiological and clinical characteristics. A comparative study of 2 cohorts (1993-1998 versus 2002-2005). Rev Iberoam Micol. 2009; 26(3): 184-8[DOI][PubMed]
  • 23. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev. 1996; 9(4): 499-511[PubMed]
  • 24. Radentz WH. Opportunistic fungal infections in immunocompromised hosts. J Am Acad Dermatol. 1989; 20(6): 989-1003[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments